Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower ...

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO and cut its full-year sales and profit guidance.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss. Together, these blockbuster drugs made Novo the most valuable publicly ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Danish leader will face a challenging landscape among competitors ...